Clinical Trials in the EU
This article was originally published in SRA
New database launched as legislation is still being transposed
You may also be interested in...
The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.
Coherus BioSciences is aiming to translate the success of its comprehensive biosimilar pegfilgrastim strategy to adalimumab, with plans to capture at least 10% of the US market upon formation in 2023. Management summarized the firm’s expectations during the company’s fourth-quarter earnings call, which revealed a downturn in pegfilgrastim sales and profitability.
Executives On The Move: PYC Therapeutics Gets Chief Development Officer, New Chief Commercial Officer At Everest Medicines
New Directors Join Ambrx, Synedgen and Cogent Biosciences.